Clin2
NCT07059091Possibly a fitRecruiting

Omalizumab for COPD with allergies

Chronic Obstructive Pulmonary Disease (COPD)Allergies

Treatments studied

Part of Immune system & allergy, Lungs & breathing clinical trials.

This trial tests if omalizumab, an allergy medication, can help people with COPD who have allergies to common indoor triggers like cat, dog, mouse, cockroach, or dust mite. It aims to reduce flare-ups and improve breathing.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
334 people
Ages
40 years and older
Study type
Interventional

Who can take part

  • You are over 40 years old
  • You have COPD and use two or more long-acting inhalers
  • You have smoked at least 10 pack-years (for example, 1 pack a day for 10 years)
  • Your COPD symptoms are moderate to severe, or you have had a flare-up in the past year
  • You are allergic to one or more common indoor allergens and are exposed to that allergen at home
  • Your lung function test shows a low ratio and percent predicted

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06943534Recruiting· Phase 2
Omalizumab for severe food allergies: weight-based dosing study

This trial tests if omalizumab (a drug that blocks allergy reactions) can help people with multiple food allergies. You might qualify if you have severe allergies to at least two foods like peanut, tree nuts, egg, or milk.

Boston, Massachusetts
NCT07053423Recruiting· Phase 4
Dupilumab for COPD with airway inflammation

This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.

Birmingham, Alabama
NCT06934200Recruiting· Phase 2
Xolair for food allergy in people with high IgE

This study tests if omalizumab (Xolair), an injectable medicine that blocks allergy antibodies, can help people with food allergies tolerate small amounts of their trigger foods. It's for people with high total IgE levels who were not eligible for a related study.

Baltimore, Maryland
NCT06027073Not yet recruiting· Phase 4
Biologics and allergy drops for dust mite asthma

This trial tests combining a biologic drug (omalizumab) with allergy drops (sublingual immunotherapy) to see if they work better together for people with moderate asthma triggered by dust mites. It may help control your asthma symptoms better.

NCT06618963Recruiting· Phase 4
Omalizumab for food allergy skin effects

This trial tests if omalizumab (Xolair) can improve skin reactions in people with food allergies. It may help reduce allergic symptoms triggered by foods like peanut, egg, or milk.

Denver, Colorado
NCT05332067Recruiting· Phase 2
Omalizumab to prevent future asthma flare-ups before they start

This trial studies whether starting omalizumab before asthma flare-ups begin can reduce how often children get worsening asthma that needs strong steroid medicine. It is for children with persistent asthma who have signs of allergic/asthma triggers and recent flare-up history.

Washington D.C., District of Columbia

Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.